Stockreport

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med,...

Molecular Partners AG - American Depositary Shares  (MOLN) 
PDF MP0712 treatment leads to strong tumor growth inhibition with a good safety profile in vivo ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 27, 2024 (GLOBE NE [Read more]